Share this article
Share this article
TITUSVILLE, N.J., Jan. 21, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen s rilpivirine and ViiV Healthcare s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.
CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resist
Share this article
Share this article
ATLANTA, Jan. 22, 2021 /PRNewswire/ MetroCity Bankshares, Inc. ( MetroCity or the Company ) (NASDAQ: MCBS), holding company for Metro City Bank (the Bank ), today reported net income of $9.5 million, or $0.37 per diluted share, for the fourth quarter of 2020, compared to $9.4 million, or $0.36 per diluted share, for the third quarter of 2020, and $10.7 million, or $0.42 per diluted share, for the fourth quarter of 2019. For the year ended December 31, 2020, the Company reported net income of $36.4 million, or $1.41 per diluted share, compared to $44.7 million, or $1.81 per diluted share, for the year ended December 31, 2019.
Fourth Quarter 2020 Highlights:
Annualized return on average assets was 2.14%, compared to 2.20% for the third quarter of 2020 and 2.57% for the fourth quarter of 2019.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Collection Sites Announces Partnership with Health and Wellness Expert, Heidi Powell
Medivolve Inc.January 21, 2021 GMT
TORONTO, Jan. 21, 2021 (GLOBE NEWSWIRE) Medivolve, Inc. (“Medivolve”) (NEO:MEDV; OTC:COPRF; FRA:4NC) is pleased to announce the launch of a partnership between its wholly owned subsidiary, Collection Sites, LLC, and Heidi Powell, fitness and transformation expert from ABC’s ‘Extreme Weight Loss’ show. Furthering its dedication to flatten the curve against the novel coronavirus, Collection Sites and Heidi Powell have launched two COVID-19 testing centers in Austin, Texas and Tempe, Arizona providing convenient access to rapid antibody and antigen tests. As part of the partnership, Heidi Powell has paid an upfront fee to launch the test centre in exchange for a small royalty. Through this partnership, Collection Sites customers nationwide will have access to H
First Cobalt Closes $9.8 Million Financing
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES First Cobalt Corp. is pleased to announce that it has closed its previously announced bought deal offering of units of the Company . The Offering was conducted by a syndicate of underwriters led by Eight Capital, together with CIBC World Markets Inc., Canaccord Genuity Corp., Red Cloud Securities Inc. and Mackie Research Capital … /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES/
First Cobalt Corp. (TSXV: FCC) (OTCQX: FTSSF) (the “Company”) is pleased to announce that it has closed its previously announced bought deal offering (the “Offering”) of units of the Company (the “Units”). The Offering was conducted by a syndicate of underwriters led by Eight Capital, together with CIBC World Markets Inc., Canaccord Genuity Corp., Red Cloud Securities Inc. and Mackie Research Capital Corporation (coll
Investegate announcements from Calibre Mining Corp., Pavon Norte Open-Pit Mine Delivers Initial Mill Feed to Libertad Complex, Ahead of Schedule and Under Budget